Definium Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) is set to discuss its investigational drug DT120, a form of lysergide, in the fourth quarter. This follows results from a Phase 3 Panorama study, which demonstrated a 5.1-point advantage over placebo on the Hamilton Anxiety Rating Scale (HAM-A) after 12 weeks. As of September 22, the company's market value was approximately $5.42 billion.
Read More
The Panorama study involved 245 participants diagnosed with generalized anxiety disorder and marked Definium's second positive outcome in this area. The trial echoes earlier positive results from its Voyage study in August and the Emerge study in June, focused on major depressive disorder. Definium aims to file a new drug application in the first half of 2027, contingent on the upcoming FDA discussion.
In this trial, 96 adults were assigned to receive 100 micrograms of DT120, while 97 were given a placebo, and an additional 52 participants were randomized to a 50-microgram group, intended to reduce functional unblinding but not statistically analyzed for efficacy. Significant reductions in HAM-A scores were observed, with a mean decline of 9.8 points in the high-dose group compared to 4.7 points in the placebo group, achieving a placebo-adjusted difference with a p-value below 0.0001. Definium reported success in three key secondary efficacy endpoints as well.
Despite positive results, blinding issues were noted, as 95% of high-dose participants and 91% of lower-dose recipients accurately guessed their treatment assignments. Nonetheless, Definium believes that the dose-response relationship indicates efficacy beyond expectations. The FDA’s July 2026 guidance on psychedelic trials cautions that functional unblinding could introduce bias, complicating efficacy assessments.
In terms of safety, treatment-emergent adverse events occurred in 94.8% of high-dose and 62.9% of placebo recipients, with two serious adverse events in the high-dose arm reported as unrelated to the drug. Definium monitored participants for at least eight hours post-dosing, with 94% of high-dose individuals meeting the company's end-of-session criteria by the eighth hour.
As of June 30, the company had around $1.1 billion in cash and investments, sufficient to support operations until 2030. Differentiating itself, Compass Pathways plc, another firm in the psychedelic space, is seeking FDA review for its COMP360 psilocybin treatment aimed at treatment-resistant depression. Definium plans to discuss its regulatory pathway at a pre-application meeting with the FDA in the fourth quarter of 2026.